|
業務類別
|
Biotechnology |
|
業務概覽
|
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indicationsas graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D). |
| 公司地址
| 3060 Pegasus Park Drive, Building 6, Dallas, TX, USA, 75247 |
| 電話號碼
| +1 310 618-6994 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.fortebiorx.com |
| 員工數量
| 14 |
| Mr. Antony A. Riley |
Chief Financial Officer |
美元 434.73K |
30/04/2025 |
| Dr. Paul A. Wagner, PhD |
Chairman of the Board, President and Chief Executive Officer |
美元 644.28K |
30/04/2025 |
|
|
| Mr. Shivpreet Singh Kapoor |
Independent Director |
30/04/2025 |
| Mr. Steven Kornfeld |
Independent Director |
30/04/2025 |
| Dr. Paul A. Wagner, PhD |
Chairman of the Board, President and Chief Executive Officer |
30/04/2025 |
| Mr. David W. Gryska, M.B.A. |
Independent Director |
30/04/2025 |
| Dr. Stephen K. Doberstein, PhD |
Independent Director |
30/04/2025 |
| Dr. Barbara K. Finck, M.D. |
Director |
30/04/2025 |
| Mr. Richard G. Vincent |
Independent Director |
30/04/2025 |
| Dr. Scott C. Brun, M.D. |
Independent Director |
30/04/2025 |
|
|
|
|
